Arrhythmia

IRHYTHM TECHNOLOGIES, INC. (NASDAQ: IRTC) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against iRhythm Technologies, Inc.

Retrieved on: 
Monday, March 25, 2024
Zio, Advertising, Arrhythmia, Letter, District court, Patient, News, Complaint, Action Replay, FDA, Court, Physician, IRTC, Security (finance)

If you purchased or acquired iRhythm common stock, and/or would like to discuss your legal rights and options please visit iRhythm Technologies, Inc.

Key Points: 
  • If you purchased or acquired iRhythm common stock, and/or would like to discuss your legal rights and options please visit iRhythm Technologies, Inc.
  • If you wish to serve as lead plaintiff, you must move the Court no later than April 8, 2024.
  • A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
  • The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414.

IRTC Class Action Alert: Robbins LLP Reminds Investors of Pending Lead Plaintiff Deadline – April 8, 2024 – in iRhythm Technologies, Inc. Class Action

Retrieved on: 
Thursday, March 21, 2024
Zio, Patient, Complaint, Growth, LLP, Arrhythmia, IRTC, Person

For more information, submit a form , email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.

Key Points: 
  • For more information, submit a form , email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.
  • The Allegations: According to the complaint, during the class period, iRhythm represented to investors that the Zio AT monitor was a real-time monitor intended for a target audience of high-risk patients.
  • As a result of these representations, the price of iRhythm common stock traded at artificially inflated prices throughout the class period.
  • A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation.

Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Regulatory and Corporate Update

Retrieved on: 
Thursday, March 21, 2024
Research, American Heart Association, Letter, Arrhythmia, Refusal, Offering, Paroxysmal supraventricular tachycardia, Safety, Atrial fibrillation, New Drug Application, Patient, Shanda, NDA, Aes, Science, Net, RTF, Investment, AHA, Milestone, Revera, FDA, Pharmaceutical industry

MONTREAL and CHARLOTTE, N.C., March 21, 2024 (GLOBE NEWSWIRE) --  Milestone Pharmaceuticals Inc. (Nasdaq: MIST) today reported financial results for the fourth quarter and year ended December 31, 2023 and provided a regulatory and corporate update.

Key Points: 
  • - FDA reiterated prior guidance on regulatory pathway for AFib-RVR, End of Phase 2 Meeting expected mid-2024
    MONTREAL and CHARLOTTE, N.C., March 21, 2024 (GLOBE NEWSWIRE) --  Milestone Pharmaceuticals Inc. (Nasdaq: MIST) today reported financial results for the fourth quarter and year ended December 31, 2023 and provided a regulatory and corporate update.
  • There was no revenue recorded for the fourth quarter of 2023, compared with $3.5 million the fourth quarter of 2022.
  • Commercial expense for the fourth quarter of 2023 was $5.0 million, compared with $2.6 million for the prior year period.
  • For the fourth quarter of 2023, net loss was $13.6 million, compared to $13.2 million for the prior year period.

IRHYTHM TECHNOLOGIES, INC. (NASDAQ: IRTC) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against iRhythm Technologies, Inc.

Retrieved on: 
Monday, March 18, 2024
Zio, Advertising, Arrhythmia, Letter, District court, Patient, News, Complaint, Action Replay, FDA, Court, Physician, IRTC, Security (finance)

If you purchased or acquired iRhythm common stock, and/or would like to discuss your legal rights and options please visit iRhythm Technologies, Inc.

Key Points: 
  • If you purchased or acquired iRhythm common stock, and/or would like to discuss your legal rights and options please visit iRhythm Technologies, Inc.
  • If you wish to serve as lead plaintiff, you must move the Court no later than April 8, 2024.
  • A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
  • The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414.

Tenaya Therapeutics Announces Publication of TN-401 Gene Therapy Preclinical Data in Nature Communications Medicine

Retrieved on: 
Monday, March 18, 2024
PKP2, Arrhythmogenic cardiomyopathy, Arrhythmia, Survival, Disease, Risk, Patient, SAN, Hope, Quality of life, Protein, ACM, Clinical trial, Therapy, Heart, Cardiomyopathy, Safety, Vaccine

SOUTH SAN FRANCISCO, Calif., March 18, 2024 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced the publication of its preclinical research related to its gene therapy candidate, TN-401, in the current issue of Nature Communications Medicine.

Key Points: 
  • TN-401 is an adeno-associated virus serotype 9 (AAV9)-based gene therapy being developed for the treatment of arrhythmogenic right ventricular cardiomyopathy (ARVC) caused by Plakophilin-2 (PKP2) gene mutations.
  • TN-401 is designed to deliver a functional PKP2 gene to heart cells where it works to restore normal protein levels in order to halt or even reverse disease after a single dose.
  • “Following a single infusion of our AAV9-based PKP2 gene therapy in a severe knock-out mouse model of the disease, PKP2 protein levels were restored.
  • Tenaya is currently also conducting the RIDGE™ global non-interventional natural history and serotype study of PKP2-associated ARVC.

IRHYTHM 72 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against iRhythm Technologies, Inc. - IRTC

Retrieved on: 
Saturday, April 6, 2024
Class Action Lawsuit, Professional Services, Legal, Zio, Letter, KSF, Risk, District court, Patient, News, Pension, Arrhythmia, Special warfare combatant-craft crewmen, Marketing, FDA, Court, IRTC

This action is pending in the United States District Court for the Northern District of California.

Key Points: 
  • This action is pending in the United States District Court for the Northern District of California.
  • The case is Glazing Employers and Glaziers’ Union Local #27 Pension and Retirement Fund v. iRhythm Technologies, Inc., No.
  • About Kahn Swick & Foti, LLC
    KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation’s premier boutique securities litigation law firms.
  • KSF has offices in New York, Delaware, California, Louisiana and New Jersey.

Vektor Medical Announces Publication of vMap Study Results in Journal of Cardiovascular Electrophysiology

Retrieved on: 
Tuesday, April 2, 2024
Health, FDA, Technology, Photography, Health Technology, Artificial Intelligence, Cardiology, Arrhythmia, Artificial intelligence, Patient, Fluoroscopy, Journal, Medicine, AI, Medical imaging

Vektor Medical, a pioneer in non-invasive, AI-based arrhythmia analysis technology, today announced the publication of data in the Journal of Cardiovascular Electrophysiology (JACE) demonstrating vMap’s ability to reduce the time from mapping to treatment, procedure duration, and fluoroscopy when treating cardiac arrhythmia patients with ablation therapy.

Key Points: 
  • Vektor Medical, a pioneer in non-invasive, AI-based arrhythmia analysis technology, today announced the publication of data in the Journal of Cardiovascular Electrophysiology (JACE) demonstrating vMap’s ability to reduce the time from mapping to treatment, procedure duration, and fluoroscopy when treating cardiac arrhythmia patients with ablation therapy.
  • The study , “Impact Of Artificial Intelligence Arrhythmia Mapping on Time to First Ablation, Procedure Duration, and Fluoroscopy Use,” is a retrospective, case-controlled study of 28 patients with common arrhythmia types.
  • “By employing AI ECG arrhythmia mapping using 12-lead ECG data, the study shows increased procedural efficiency and improved patient safety by limiting exposure to fluoroscopy.
  • EPs can rely on vMap to reduce procedure times with increased confidence in positive outcomes.

Viz.ai and Medtronic Collaborate to Improve Post-Acute Stroke Patient Care in the United States

Retrieved on: 
Tuesday, March 26, 2024
Neurology, Cardiology, Software, Health, Artificial Intelligence, Hospitals, Health Technology, Technology, Stroke, Conductance quantum, Communication, Atrial fibrillation, Risk, Patient, AI, Arrhythmia, Medtronic, MD, Trial of the century, Viz, Service

Viz.ai, Inc., the leader in AI-powered disease detection and intelligent care coordination, today announced a strategic collaboration with Medtronic to improve the coordination of cryptogenic stroke patient care between the neurology and cardiology teams.

Key Points: 
  • Viz.ai, Inc., the leader in AI-powered disease detection and intelligent care coordination, today announced a strategic collaboration with Medtronic to improve the coordination of cryptogenic stroke patient care between the neurology and cardiology teams.
  • For stroke patients who are at risk of atrial fibrillation (“AF”) post-stroke and may need additional cardiac monitoring, stroke care teams in the U.S. will have the opportunity to use the Viz Connect™ solution, a software tool that automates the communication across disciplines, including neurology and cardiology.
  • Recent clinical study results indicate that both community hospitals and academic centers are in need of stronger, standardized care pathways between neurology and cardiology to ensure that stroke patients receive guideline-directed therapy.
  • According to the DiVERT Stroke clinical study, only 16% of stroke patients from community hospitals and 34% of patients at academic centers received a cardiology consult.1
    “Through our collaboration with Medtronic, we have the opportunity to bring cardiology and neurology closer together by using software tools that help facilitate stroke patient care,” said Chris Mansi, MD, CEO and co-founder at Viz.ai.

HeartBeam Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Wednesday, March 20, 2024
Cardiology, Software, Health, Artificial Intelligence, Medical Devices, Health Technology, Technology, Clinical Trials, Element, Research, Microsoft, Algorithm, Arrhythmia, Apple, Communication, Patent, Webcast, Patient, Lead, Consultant, Artificial intelligence, G&A, AI, United States patent law, Doctor of Philosophy, Deep learning, Abstract, FDA, ECG, Medical device

HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through the power of personalized insights, has reported its financial and operational results for the fourth quarter and full year ended December 31, 2023.

Key Points: 
  • HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through the power of personalized insights, has reported its financial and operational results for the fourth quarter and full year ended December 31, 2023.
  • Research and development expenses for the fourth quarter of 2023 were $2.0 million, compared to $1.6 million for the fourth quarter of 2022.
  • General and administrative expenses for the fourth quarter of 2023 were $2.1 million compared to $2.1 million for the fourth quarter of 2022.
  • Net loss for the fourth quarter of 2023 was $3.9 million, compared to a net loss of $3.7 million for the fourth quarter of 2022, and $14.6 million for the full year 2023 compared to $13.0 million in the same period of 2022.

AstraZeneca caps patient out-of-pocket costs at $35 per month for its US inhaled respiratory portfolio

Retrieved on: 
Monday, March 18, 2024
Biotechnology, Medical Devices, Health, Pharmaceutical, Health Insurance, Diabetes, Blood pressure, Depression, Arrhythmia, Hypokalemia, ICS, Anaphylaxis, Angioedema, Congress, Moyamoya disease, AstraZeneca, MAOI, Hyperthyroidism, Risk, ECG, Incidence, Headache, Immunosuppression, Patient, QT interval, Chronic obstructive pulmonary disease, Inhalation, Chickenpox, Research, Budesonide, System, Liver, Cough, Rash, Infection, Salbutamol, Water, Cataract, Adrenal gland, Measles, Safety, Bronchospasm, COPD, Glaucoma, Use, Catherine Disher, Fatality, Monoamine oxidase inhibitor, Hypertension, Medicine, Pharmaceutical industry

AstraZeneca announced it will expand the savings programs for its entire US inhaled respiratory portfolio, helping eligible patients pay no more than $35 per month for their medicine.

Key Points: 
  • AstraZeneca announced it will expand the savings programs for its entire US inhaled respiratory portfolio, helping eligible patients pay no more than $35 per month for their medicine.
  • We remain dedicated to addressing the need for affordability of our medicines, but the system is complex and we cannot do it alone.
  • The Company will continue to provide discounts and rebates off the list price to help patients afford its inhaled respiratory medicines.
  • AstraZeneca remains dedicated to transforming patient outcomes, while ensuring access and affordability of our innovative medicines.